HCV Treatment
EASL 2010: Achillion Announces Additional Promising Data from Phase 1b Trial of HCV Protease Inhibitor ACH-1625
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 21 May 2010 13:56
- Written by Achillion Pharmaceuticals
Achillion Pharmaceuticals this month announced further interim data from an ongoing Phase 1b trial of the company's investigational hepatitis C virus (HCV) NS3 protease inhibitor ACH-1625. At the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) last month in Vienna, researchers presented early data showing that in patients with genotype 1 chronic hepatitis C, ACH-1625 monotherapy at doses of 500 mg and 600 mg twice-daily for 5 days decreased HCV viral load by approximately 4 log and was generally well-tolerated with no drug-related serious adverse events. The latest data extend these findings to people taking doses of 200 mg twice-daily and 600 mg once-daily.
EASL 2010: European Study Finds More than Half of HIV/HCV Coinfected Patients Do Not Receive Treatment despite Advanced Fibrosis
- Details
- Category: HCV Treatment
- Published on Tuesday, 11 May 2010 12:56
- Written by Liz Highleyman
A majority of HIV positive individuals with chronic hepatitis C virus (HCV) coinfection are not treated for hepatitis C for a variety of reasons ranging from patient choice to provider concerns about adherence, active substance use, or mental illness, according to a study presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) last month in Vienna. The researchers noted, however, that studies demonstrate acceptable treatment success for such patients in real-life clinical practice.
HCV Polymerase Inhibitor IDX184, Protease Inhibitor IDX320 and Triple Combination Show Promising Antiviral Activity
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 04 May 2010 00:00
- Written by Liz Highleyman
Two investigational direct-acting drugs for hepatitis C virus (HCV) infection -- the polymerase inhibitor IDX184 and the protease inhibitor IDX320 -- demonstrated good antiviral activity in a Phase 2a clinical trial and in laboratory and animal studies, respectively, researchers reported at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) last month in Vienna. Another in vitro study showed that these 2 drugs plus IDX375 (another polymerase inhibitor that works a different way) or an experimental NS5A inhibitor exhibited enhanced or synergistic viral suppression.
EASL 2010: PROTECT Study Finds One-third of Liver Transplant Patients Achieve Sustained Response to Pegylated Interferon plus Ribavirin
- Details
- Category: Approved HCV Drugs
- Published on Tuesday, 04 May 2010 12:56
- Written by Liz Highleyman
Combination therapy with pegylated interferon alfa-2b (PegIntron) plus ribavirin led to sustained virological response (SVR) in about 30% of hepatitis C patients after liver transplantation, according to final results from the PROTECT study reported at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) last month in Vienna. A similar proportion, however, were unable to complete therapy due to adverse events.
HCV NS5A Inhibitor BMS-790052 Suppresses Viral Replication in Combination with Pegylated Interferon/ribavirin
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 30 April 2010 00:00
- Written by Liz Highleyman
BMS-790052, Bristol-Myers Squibb's investigational hepatitis C virus (HCV) NS5A inhibitor, demonstrated potent early antiviral activity at 4 and 12 weeks when combined with the standard regimen of pegylated interferon plus ribavirin in previously untreated patients with HCV genotype 1, investigators reported at the at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) this month in Vienna.
More Articles...
- Investigational HCV Inhibitor TMC435 Demonstrates Promising Safety and Efficacy in Phase 1 Study
- Older Hepatitis C Patients Have More Side Effects from Interferon-based Therapy, but Many Can Achieve Sustained Response
- CROI 2010: IL28B Gene Variation Linked to Spontaneous Clearance and Treatment Response in HIV/HCV Coinfected People
- Can Some Genotype 1 Chronic Hepatitis C Patients Benefit from Shorter Interferon-based Treatment?
Web Design and Development by